8-K: 1847 Holdings Completes $11.1 Million Public Offering of Units

1847 Holdings LLC successfully closed a public offering, raising $11.1 million through the sale of units consisting of common shares or pre-funded warrants and two series of warrants.

Summary

• 1847 Holdings LLC has completed a public offering, generating gross proceeds of $11.1 million.
• The offering consisted of 8,809,512 units priced at $1.26 each.
• Each unit included one common share or a pre-funded warrant, a Series A warrant, and a Series B warrant.
• The pre-funded warrants have an exercise price of $0.01 per share.
• The Series A warrants have an exercise price of $1.90 per share.
• The Series B warrants have an exercise price of $2.52 per share.
• The offering closed on October 30, 2024.
• Spartan Capital Securities, LLC acted as the sole placement agent.
• After deducting fees and expenses, the company received net proceeds of approximately $9.9 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully completed a capital raise, but there are some potential negatives such as dilution and the cost of the offering. The company's future performance will depend on how it uses the funds.

Positives

• The company successfully raised a significant amount of capital through the public offering.
• The offering included multiple types of securities, potentially appealing to a broader range of investors.
• The pre-funded warrants provide immediate capital with a low exercise price.
• The warrants offer potential future upside for investors if the stock price increases.

Negatives

• The company incurred significant fees and expenses, reducing the net proceeds from the offering.
• The warrants have a reset feature that could lower the exercise price if the company effects a reverse share split in the future, potentially diluting existing shareholders.
• The Series B warrants have an adjustment feature that could lower the exercise price if the company issues common shares or equivalents at a lower price, potentially diluting existing shareholders.

Risks

• The company's share price could be negatively impacted by the issuance of new shares and warrants.
• The reset and adjustment features of the warrants could lead to further dilution of existing shareholders.
• The company's ability to maintain its listing on the NYSE American could be at risk if the share price remains low.
• The company's future performance is subject to various risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company intends to use the net proceeds from the offering as described in the prospectus, but specific details on the use of funds are not provided in this document.

Management Comments

• 1847 Holdings investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises or lower-middle market businesses with limited exit options despite the intrinsic value of their business.
• Given this dynamic, 1847 Holdings can consistently acquire businesses it views as solid for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems of those businesses in order to improve operations.

Industry Context

This announcement reflects a common strategy for smaller public companies to raise capital through the issuance of units, which include common shares and warrants. The structure of the offering, with pre-funded warrants and multiple series of warrants, is designed to attract different types of investors and provide flexibility for the company.

Comparison to Industry Standards

• The use of units consisting of common shares and warrants is a common structure for capital raises by small-cap companies, similar to offerings by companies like Cassava Sciences (SAVA) and Ocugen (OCGN).
• The placement agent fee of 8% and expense allowance of 1% are within the typical range for such offerings, comparable to fees charged by underwriters in similar deals.
• The warrant exercise prices and terms are structured to provide potential upside for investors, similar to warrants issued by companies like Context Therapeutics (CNTX) and Agenus (AGEN).
• The inclusion of pre-funded warrants is a less common feature, but it is used by companies seeking immediate capital while providing investors with the option to convert to common shares at a later date, similar to offerings by companies like Xometry (XMTR).
• The potential for exercise price adjustments in the warrants is a common feature to protect investors from dilution, similar to anti-dilution provisions in warrants issued by companies like Amyris (AMRS) and Veru (VERU).

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's increased financial stability.
• Customers and suppliers may see improved operations and service due to the company's increased resources.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will use the net proceeds from the offering as described in the prospectus.
• The company will need to manage the potential dilution from the exercise of warrants.
• The company will need to maintain its listing on the NYSE American.

Key Dates

Keywords

public offering, common shares, pre-funded warrants, warrants, capital raise, securities, placement agent, dilution, NYSE American, investment